Search alternatives:
mean decrease » a decrease (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
wt decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
Showing 681 - 700 results of 32,589 for search '(( 50 ((ns decrease) OR (we decrease)) ) OR ( 5 ((wt decrease) OR (mean decrease)) ))', query time: 1.02s Refine Results
  1. 681
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 682
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 683
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 684
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 685
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 686
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 687
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 688
    E<sub>50</sub> values of angle.

    E<sub>50</sub> values of angle. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  9. 689
    Curve fitting of E<sub>50</sub>.

    Curve fitting of E<sub>50</sub>. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  10. 690
    Fitting curves of E<sub>50</sub>.

    Fitting curves of E<sub>50</sub>. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  11. 691
    E<sub>50</sub> values of size.

    E<sub>50</sub> values of size. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  12. 692
    E<sub>50</sub> fluctuation coefficient.

    E<sub>50</sub> fluctuation coefficient. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  13. 693
    Fitting relationship of E<sub>50</sub>.

    Fitting relationship of E<sub>50</sub>. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  14. 694
    Fitting curve of E<sub>50</sub>.

    Fitting curve of E<sub>50</sub>. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  15. 695
    AMPK phosphorylation and AC5 expression in rat AVMs in response to AMPK activation.

    AMPK phosphorylation and AC5 expression in rat AVMs in response to AMPK activation. by Anne Garnier (130125)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 696
    Decreased ovary size and defective oogenesis following specific targeting of <i>Hdac2</i> and reduction of <i>Hdac1</i> in oocytes.

    Decreased ovary size and defective oogenesis following specific targeting of <i>Hdac2</i> and reduction of <i>Hdac1</i> in oocytes. by Pengpeng Ma (389371)

    Published 2013
    Save to List
    Saved in:
  17. 697
    Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018.

    Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018. by Getachew Ossabo Babore (10788843)

    Published 2021
    Save to List
    Saved in:
  18. 698
    File S1 - FLZ Alleviates the Memory Deficits in Transgenic Mouse Model of Alzheimer’s Disease via Decreasing Beta-Amyloid Production and Tau Hyperphosphorylation

    File S1 - FLZ Alleviates the Memory Deficits in Transgenic Mouse Model of Alzheimer’s Disease via Decreasing Beta-Amyloid Production and Tau Hyperphosphorylation by Xiu-Qi Bao (479278)

    Published 2013
    Save to List
    Saved in:
  19. 699
    Expression of vTR harboring the mutant template (AU5) decreases cell proliferation of an avian cancer cell line.

    Expression of vTR harboring the mutant template (AU5) decreases cell proliferation of an avian cancer cell line. by Benedikt B. Kaufer (341018)

    Published 2013
    Save to List
    Saved in:
  20. 700
    The T-type channel antagonist Ni<sup>2+</sup> decreases adult turtle motoneuron excitability.

    The T-type channel antagonist Ni<sup>2+</sup> decreases adult turtle motoneuron excitability. by Martha Canto-Bustos (634777)

    Published 2014
    Save to List
    Saved in:

Search Tools: